Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.
A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.
Lee
Seung Tae
ST
Department of Internal Medicine and BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Jang
Joon Ho
JH
Cheong
June-Won
JW
Kim
Jin Seok
JS
Maemg
Ho-Young
HY
Hahn
Jee Sook
JS
Ko
Yun Woong
YW
Min
Yoo Hong
YH
D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008212:Lymphocyte Depletion; D008297:Male; D008648:Mesoderm / Q000166:cytology; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor